


## MM11253

Cat. No.:	HY-108530		
CAS No.:	345952-44-5		
Molecular Formula:	C <sub>28</sub> H <sub>30</sub> O <sub>2</sub> S <sub>2</sub>		
Molecular Weight:	462.67		
Target:	RAR/RXR		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (270.17 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.1614 mL	10.8068 mL	21.6137 mL
5 mM	0.4323 mL	2.1614 mL	4.3227 mL
10 mM	0.2161 mL	1.0807 mL	2.1614 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

MM11253 is a potent and selective RAR $\gamma$  antagonist with an IC<sub>50</sub> of 44 nM. MM11253 has lower inhibition of RAR $\alpha$ , RAR $\beta$  and RXR $\alpha$ . MM11253 blocks the growth inhibitory effects of RAR $\gamma$ -selective agonists<sup>[1][3]</sup>.

#### IC<sub>50</sub> & Target

RAR $\gamma$ 44 nM (IC <sub>50</sub> )	RAR $\gamma$ 44 nM (IC <sub>50</sub> )	RAR $\gamma$ 44 nM (IC <sub>50</sub> )	RAR $\alpha$ 1000 nM (IC <sub>50</sub> )
RAR $\alpha$ 1000 nM (IC <sub>50</sub> )	RAR $\alpha$ 1000 nM (IC <sub>50</sub> )	RAR $\beta$ >1000 nM (IC <sub>50</sub> )	RAR $\beta$ >1000 nM (IC <sub>50</sub> )
RAR $\beta$ >1000 nM (IC <sub>50</sub> )	RXR $\alpha$ >1000 nM (IC <sub>50</sub> )		

#### In Vitro

MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. M I Dawson, et al. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. *Int J Cancer*. 2001 Jan 1;91(1):8-21.
- [2]. Q Le, et al. Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. *Oncogene*. 2000 Mar 9;19(11):1457-65.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA